PPARA and colitis: Importantly, ATO treatment was able to increase the colonic Ppara levels in colitis-induced mice, while infliximab-responder UC patients showed an augmented PPARA expression compared to non-responder UC patients, suggesting that PPAR-α can be a promising predictive biomarker for clinical responsiveness.